MASL Offers a Transformative Approach to Treatment
A patient-centric approach to addressing HNC throughout the patient journey
Unmet Needs in HNC
Poor overall outcomes
- High metastasis rates
- High recurrence rates
Limited therapeutic efficacy
- Few approved options
- Marginal efficacy demonstrated
- Benefit limited to a subset of the overall population
High treatment burden
- IV medications
- Safety and tolerability concerns
- Poor risk/benefit ratio for maintenance usage
Head and Neck Cancer Patients & Their Families Deserve Better Treatment Options and an Improved Quality of Life
Value Proposition for MASL
Immobilizes and destroys tumor cells
- Impairs migration and metastasis
- Impacts cell viability
Demonstrated efficacy with novel targeting
- Biomarker identifiable patients
- Unique MOA allows for use as monotherapy or in combination
Low burden with favorable safety profile
- Oral dosing
- No histological or physiological changes with chronic dosing
- No significant adverse effects identified
- Suitable for entire continuum of care